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ABSTRACT
Kaposi’s sarcoma-associated herpesvirus (KSHV, also called human herpesvirus 8) is linked to the development of Kaposi’s sar-
coma (KS), primary effusion lymphoma (PEL), and multicentric Castleman’s disease (MCD). KSHV expresses several proteins
that modulate host cell signaling pathways. One of these proteins is viral interleukin-6 (vIL-6), which is a homolog of human
IL-6 (hIL-6). vIL-6 is able to prevent apoptosis and promote proinflammatory signaling, angiogenesis, and cell proliferation.
Although it can be secreted, vIL-6 is mainly an intracellular protein that is retained in the endoplasmic reticulum (ER). We per-
formed affinity purification and mass spectrometry to identify novel vIL-6 binding partners and found that a cellular ER chaper-
one, hypoxia-upregulated protein 1 (HYOU1), interacts with vIL-6. Immunohistochemical staining reveals that both PEL and KS
tumor tissues express significant amounts of HYOU1. We also show that HYOU1 increases endogenous vIL-6 protein levels and
that HYOU1 facilitates vIL-6-induced JAK/STAT signaling, migration, and survival in endothelial cells. Furthermore, our data
suggest that HYOU1 also modulates vIL-6’s ability to induce CCL2, a chemokine involved in cell migration. Finally, we investi-
gated the impact of HYOU1 on cellular hIL-6 signaling. Collectively, our data indicate that HYOU1 is important for vIL-6 func-
tion and may play a role in the pathogenesis of KSHV-associated cancers.
IMPORTANCE
KSHV vIL-6 is detectable in all KSHV-associated malignancies and promotes tumorigenesis and inflammation. We identified a
cellular protein, called hypoxia-upregulated protein 1 (HYOU1), that interacts with KSHV vIL-6 and is present in KSHV-in-
fected tumors. Our data suggest that HYOU1 facilitates the vIL-6-induced signaling, migration, and survival of endothelial cells.
Kaposi’s sarcoma-associated herpesvirus (KSHV; human her-pesvirus 8) is the causative agent of several human malignancies,
including Kaposi’s sarcoma (KS), primary effusion lymphoma
(PEL), and multicentric Castleman’s disease (MCD) (1–4). These
malignancies often occur in the context of immunosuppression, and
as a result, KSHV-associated malignancies have increased in inci-
dence since the onset of the AIDS epidemic (5). KSHV is a member of
the gammaherpesvirus subfamily and has a double-stranded DNA
genome that expresses over 80 open reading frames (ORFs) (6).
KSHV usually exists in a latent state in which a small subset of the
viral genome is expressed. When the virus undergoes lytic reacti-
vation, all viral genes are expressed and progeny virions are pro-
duced.
It is thought that several latent and lytic genes contribute to
modulation of host cell signaling to induce tumorigenesis. One of
these genes is ORF K2, which encodes a viral homolog of human
interleukin-6 (hIL-6) called viral IL-6 (vIL-6) (7–9). vIL-6 shares
25% identity and 63% similarity to hIL-6 at the amino acid level.
vIL-6 is expressed at low levels in latently infected PEL cells and is
highly upregulated upon lytic reactivation (10–12). All KSHV-
associated malignancies have detectable vIL-6 levels (13–15).
vIL-6 expression transforms NIH 3T3 cells, and vIL-6-expressing
cells injected into mice form larger tumors than control cells (16).
Additionally, transgenic mice engineered to express vIL-6 under
the major histocompatibility complex (MHC) class I promoter
display a phenotype reminiscent of that of KSHV-associated plas-
mablastic MCD that is also dependent on mouse IL-6 expression
(17). vIL-6 drives production of hIL-6 (18) and vascular endothe-
lial growth factor (VEGF) (16) and can promote angiogenesis
(19). Importantly, vIL-6 activates signaling pathways similar to
those of human cytokines, including the JAK/STAT, mitogen-ac-
tivated protein kinase (MAPK), and phosphoinositol 3-kinase
(PI3K) pathways (20–22).
vIL-6 differs from hIL-6 in several ways: hIL-6 must bind the
IL-6 receptor (IL6R, gp80) before activation of the gp130 signal
transducer subunit, whereas vIL-6 can directly bind gp130 to in-
duce signaling (23–25); however, involvement of gp80 can en-
hance vIL-6 signaling (26). Another difference is that hIL-6 is
rapidly secreted from cells but that vIL-6 is retained primarily
within the endoplasmic reticulum (ER) (12, 27). In this compart-
ment, vIL-6 binds gp130 in a tetrameric complex to induce intra-
cellular signaling (12). The cellular ER protein calnexin has been
shown to interact with vIL-6 to stabilize vIL-6 folding and main-
tain its intracellular distribution (28). The ER transmembrane
protein vitamin K epoxide reductase complex subunit 1 variant 2
(VKORC1v2) was recently identified as an additional intracellular
binding partner of vIL-6 (29, 30). vIL-6 binds to VKORC1v2’s C
terminus, which is present in the ER lumen, but data suggest that
this binding domain is not responsible for retention of vIL-6 in the
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ER. Overexpression of VKORC1v2’s vIL-6 binding domain or de-
pletion of VKORC1v2 abrogates vIL-6’s progrowth phenotype in
PEL cells independently of gp130 signaling (29). Furthermore, it
was found that vIL-6 promotes PEL cell survival by suppressing
the proapoptotic properties of the VKORC1v2 binding partner
cathepsin D (31). This suggests that VKORC1v2 uses a mecha-
nism independent of gp130 signaling to promote vIL-6 function
and PEL cell survival.
We performed affinity purification and mass spectrometry
(MS) to identify novel binding partners of intracellular vIL-6. We
found that a protein called hypoxia-upregulated protein 1
(HYOU1; also called the 150-kDa oxygen-regulated protein, or
ORP150) is able to bind vIL-6. HYOU1 is an ER-resident chaper-
one protein that is a member of the heat shock and ER stress
protein families (32). HYOU1 is expressed in many different cell
types and can be upregulated by various cellular conditions, in-
cluding hypoxia and ER stress (32, 33). Furthermore, HYOU1 is
upregulated in some human cancers, including head and neck and
breast cancers (34, 35). The HYOU1 transcript was originally
cloned from astrocytes under hypoxic conditions (36), which
makes it a protein relevant to KSHV biology, since hypoxia plays a
role in the KSHV life cycle (37). Previous work has indicated that
HYOU1 can suppress hypoxia-induced cell death (38) and induce
angiogenesis by facilitating VEGF processing (39).
We found that HYOU1’s interaction with vIL-6 is important
for vIL-6-induced intracellular STAT3 signaling and vIL-6 expres-
sion in PEL cells. Furthermore, we show that HYOU1 is required
for several vIL-6 biological functions, including promotion of en-
dothelial cell survival and migration. We found that vIL-6 in-
creases extracellular levels of chemokine (C-C motif) ligand 2
(CCL2, also called monocyte chemoattractant protein 1, or
MCP1) in a HYOU1-dependent manner. CCL2 is implicated in
the migration and metastasis of tumor cells and the extravasation
of immune cells (40, 41). Finally, we investigated the impact of
HYOU1 on cellular hIL-6 signaling. Our results suggest that by
modulating vIL-6 function, HYOU1 may contribute to KSHV-
associated tumorigenesis, making HYOU1 an attractive target for
the treatment of KSHV-associated malignancies.
MATERIALS AND METHODS
Cell culture and generation of stable cell lines. Human embryonic kid-
ney 293 (HEK293) and HEK293T cells were cultured in Dulbecco’s mod-
ified Eagle’s medium (Corning). BCBL1 PEL cells were cultured in RPMI
1640 medium (Corning) containing 0.05 mM -mercaptoethanol. TREx
BCBL1-inducible cells expressing either empty vector or replication and
transcription activator (RTA) protein (42) were cultured in RPMI 1640
medium (Corning) containing tetracycline (Tet) system-approved fetal
bovine serum (FBS; Clontech) and 20 g/ml hygromycin B (Roche). Hu-
man telomerase reverse transcriptase-immortalized human umbilical
vein endothelial cells (hTERT-HUVEC) were cultured in EBM-2 (Lonza)
with the EBM-2 bullet supplement (Lonza) as described previously (43).
All media were additionally supplemented with 10% heat-inactivated
FBS, 1% penicillin-streptomycin (PS), and 1% L-glutamine. Charcoal-
filtered FBS was obtained from Life Technologies. Cells were transfected
with X-tremeGENE high-performance (HP) transfection reagent (Roche)
at a ratio of 2 l X-tremeGENE to 1 g plasmid DNA as per the manu-
facturer’s protocol. Cells were transfected with 50 to 100 nM small inter-
fering RNA (siRNA) by utilizing Lipofectamine RNAiMAX (Invitrogen)
per the manufacturer’s protocol. For lentiviral transductions, adherent
cells were grown to 70% confluence and inoculated with lentivirus in the
presence of 8 g/ml Polybrene. Spinoculation was used for PEL cell trans-
ductions as previously described (44). All transfection and transduction
media were incubated for 48 to 72 h to allow for protein expression or
knockdown. hTERT-HUVEC and HEK293 cells stably expressing an
empty vector or vIL-6 were generated by lentiviral transduction. HEK293
cells stably expressing a nontargeting short hairpin RNA (shRNA) or a
HYOU1-targeting shRNA plasmid (described below) were also generated
by lentiviral transduction. For all stable cells, media were changed 24 h
postransduction and the puromycin concentration was increased from
0.1 g/ml to a final concentration of 0.5 g/ml for hTERT-HUVEC and
1.0 g/ml for HEK293 cells over 2 weeks.
Plasmids, lentiviral vectors, shRNAs, and siRNAs. The pcDNA3.1-
vIL-6-His clone was a kind gift from Yuan Chang and Patrick Moore. A
C-terminal FLAG tag was added to vIL-6 and cloned into the pcDNA3.1
eukaryotic expression vector (Invitrogen). pSG5-based eukaryotic ex-
pression vectors for untagged hIL-6 and hIL-6 with an ER-targeting motif
containing KDEL and additional sequences (45) were a kind gift from
John Nicholas and were previously described (12). The nontargeting con-
trol (NTC) siRNA duplex was purchased from Dharmacon (catalog number
D001810-01), and the HYOU1-targeting siRNA duplex was designed and
purchased from Invitrogen (catalog number NM_001130991_stealth_455)
by utilizing the Block-iT RNA interference (RNAi) designer as previously
described (46). Plasmids for the pLKO.1 NTC shRNA and a HYOU1-target-
ing shRNA (reagent number TRCN0000029220) were purchased from
Sigma and used to generate lentivirus. FLAG-tagged vIL-6 was cloned into
the lentiviral vector pSuper-CMV puro (Invitrogen). All lentiviruses were
produced using the ViraPower lentiviral expression system (Invitrogen)
as per the manufacturer’s instructions.
MS, immunoprecipitations, and Western blotting. Twenty million
293T cells were transfected with pcDNA3 or vIL-6 expression vectors for
48 h. Cells were harvested on ice in NP-40 lysis buffer (0.1% NP-40, 150
mM NaCl, 50 mM Tris HCl, pH 8.0, 30 mM -glycerophosphate, 50 mM
NaF, 1 mM Na3VO4, 1 Roche protease inhibitor tablet per 50 ml), fol-
lowed by one freeze-thaw cycle. Samples were clarified by centrifugation
at 16,000  g for 10 min, and protein content was determined by Bradford
assay (Bio-Rad). Equal amounts of protein were loaded on FLAG anti-
body-conjugated beads (EZview red anti-FLAG M2 affinity gel; Sigma)
and rocked at 4°C overnight. Beads were washed twice with lysis buffer,
followed by 2 washes with 50 mM NH4HCO3. Samples were eluted with
3-FLAG peptide (Sigma) diluted in 50 mM NH4HCO3 and 0.1% PPS
Silent surfactant (Protein Discovery). Samples were treated with 5 mM
dithiothreitol at 60°C for 15 min. Proteins were trypsinized using the
filter-aided sample prep (FASP) protein digestion protocol (Protein Dis-
covery), and tryptic peptides were separated by a nanoAquity UPLC sys-
tem (Waters Corp.) with a 2-cm trapping column and a self-packed
25-cm analytical column (75-m internal diameter; Michrom Magic C18
beads of 5.0-m particle size, 100-Å pore size) at room temperature. The
flow rate was 350 nl/min over a gradient of 1% buffer B (0.1% formic acid
in acetonitrile) to 35% buffer B in 200 min. A full mass spectrum scan (300
to 2,000 mass/charge ratio [m/z]) was acquired in an LTQ-Orbitrap Velos
mass spectrometer (Thermo Scientific) at a resolution setting of 60,000;
data-dependent tandem mass spectrometry (MS2) spectra were acquired
by collision-induced dissociation with the 15 most intense ions. All raw
data were searched with the Sorcerer-SEQUEST server (Sage-N Research)
against the human UniProtKB/Swiss-Prot sequence database. Search pa-
rameters used were a precursor mass between 400 and 4,500 atomic mass
units (amu), up to 2 missed cleavages, a precursor ion tolerance of 3 amu,
semitryptic digestion, a static carbamidomethyl cysteine modification,
and variable methionine oxidation. False discovery rates (FDRs) were
determined by ProteinProphet, and minimum protein probability cutoffs
resulting in a 1% FDR were used.
For HYOU1 immunoprecipitations, cell lysates containing equal
amounts of protein were precleared by incubation with protein A beads
and normal rabbit IgG. Beads were pelleted, and supernatants were incu-
bated with 8 l HYOU1 antibody or rabbit IgG for 5 h prior to the addi-
tion of 50 l protein A beads overnight. Beads were pelleted and washed
twice with lysis buffer and twice with cold Tris-buffered saline (TBS).
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Bound proteins were eluted by boiling the beads in Laemmli buffer for 5
min. For FLAG–vIL-6 immunoprecipitation, HEK293 cells stably ex-
pressing the empty vector or vIL-6 were transfected with 75 nM NTC or
HYOU1-targeting siRNA for 72 h. Equal amounts of cell lysates were
precleared by protein A beads, and normal rabbit IgG was then incubated
with 50 l FLAG antibody-conjugated beads overnight. Bound proteins
were eluted with 3X FLAG peptide. All immunoprecipitation inputs and
eluates were resolved on 10% SDS-PAGE gels and transferred to nitrocel-
lulose membranes. Membranes were blocked with 5% nonfat dry milk in
1 TBS-0.1% Tween 20 (TBST) followed by overnight incubation with
primary antibody at 4°C. Blots were then incubated with the appropriate
horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at
room temperature. Blots were developed with Pico West chemilumines-
cent reagent (Thermo). Primary antibodies used were FLAG (Bethyl Lab-
oratories; catalog number A190-101P), actin (Santa Cruz; sc-1615), tubu-
lin (Cell Signaling; 9099), phospho-STAT3 Tyr705 (Cell Signaling; 9131),
total STAT3 (Cell Signaling; 4904), HYOU1 (Abcam; ab134944), human
IL-6 (Abcam; ab32530), gp130 (Santa Cruz; sc-655), latency associated
nuclear antigen (LANA) (Advanced Biotechnologies; 13-210-100), RTA
(a gift from Ren Sun), K8.1 (Advanced Biotechnologies; 13-212-100), and
vIL-6 (Advanced Biotechnologies; 13-214-050). Anti-rabbit, anti-mouse,
anti-rat (Cell Signaling), and anti-goat (Santa Cruz) HRP-conjugated sec-
ondary antibodies were used. Normal rabbit IgG (Santa Cruz; sc-2027)
and protein A beads (Santa Cruz; sc-2003) were used for preclearing im-
munoprecipitation samples.
Immunohistochemistry. Immunohistochemical staining was carried
out as described previously (47). PEL xenograft tumors were obtained
from a previous study (47). Prepared sections of confirmed KSHV-posi-
tive lesions from patients with KS (specimens 30035001 and 30035006)
were obtained from the AIDS and Cancer Specimen Resource (ACSR).
For HYOU1 staining, slides were deparaffinized and rehydrated and then
incubated in 3% H2O2 in 10% methanol. Antigen retrieval was accom-
plished by boiling sections in 1 mM EDTA (pH 8.0) for 10 min. Slides were
incubated with blocking buffer (10% normal horse serum, 5% bovine
serum albumin [BSA], 0.3% Triton X-100) for 1 h, followed by overnight
incubation with HYOU1 antibody (1:100) or blocking buffer as a negative
control. Sections were washed and incubated with biotinylated goat anti-
rabbit secondary antibody for 1 h, followed by signal amplification with
the Vectastain ABC rabbit IgG kit (Vector Laboratories). Sections were
stained with 3,3=-diaminobenzidine (DAB) peroxide substrate according
to the manufacturer’s protocol (Vector Laboratories). For LANA staining,
antigen retrieval was accomplished by boiling sections in Retrievagen A,
pH 6.0 (BD Pharmingen). Slides were incubated in blocking buffer (1.5%
rabbit serum, 1% BSA, 0.1% Triton X-100, 0.05% Tween 20, 0.1% gelatin
from cold-water fish skin in 1 phosphate-buffered saline [PBS]) for 1 h,
followed by overnight incubation with LANA antibody diluted 1:100 in
antibody buffer (1% BSA, 0.1% Triton X-100, 0.1% gelatin from cold-
water fish skin in 1 PBS) or plain antibody buffer for the negative con-
trol. Sections were washed and incubated with biotinylated rabbit anti-rat
secondary antibody for 30 min, followed by signal amplification with the
Vectastain ABC rat IgG kit. Slides were stained with NovaRED substrate
according to the manufacturer’s protocol (Vector Laboratories). All slides
were counterstained with hematoxylin. Slides were imaged using a Leica
DM LA histology microscope with 20/0.25-numeric-aperture (NA) and
40/0.75-NA objectives.
Scratch assay. Stable empty-vector- or vIL-6-expressing hTERT-HU-
VEC were plated at 1.5  105 cells/well of a 6-well dish. The following day,
cells were transduced with lentivirus expressing NTC or HYOU1-target-
ing shRNA. Media were changed after 24 h, and 48 h postransduction,
cells were serum starved overnight with plain EBM-2. The monolayer was
scratched with a P10 pipette tip, and a Nikon Eclipse Ti inverted micro-
scope was used to obtain bright-field images of the cells at 40 or 100
magnification at the time points indicated below. ImageJ software (NIH)
was used to quantify the area of each scratch over time.
CCL2 ELISA. Stable empty-vector- or vIL-6-expressing hTERT-
HUVEC were plated at 1.2  105 cells/well of a 6-well dish. The following
day, cells were transfected with 100 nM NTC or HYOU1-targeting siRNA.
Seventy-two hours posttransfection, media were replaced with serum-free
EBM-2 without supplements for 48 h. Following the harvest, the media
were cleared of debris by centrifugation and a CCL2 enzyme-linked im-
munosorbent assay (ELISA) was carried out per the manufacturer’s pro-
tocol (Life Technologies). Samples were all run in triplicate. Absorbance
was read at 450 nm on a VersaMax tunable microplate reader (Molecular
Devices), and a standard curve was generated using a best-fit power trend-
line in Microsoft Excel. Error bars represent the standard deviations, and
CCL2 concentrations were compared using a two-tailed Student t test,
with a P of 0.05 considered significant. Results are representative of at
least 3 experiments.
Survival assay. Stable empty-vector- or vIL-6-expressing hTERT-
HUVEC were plated at 1.2  105 cells/well of a 6-well dish. The following
day, cells were transfected with 100 nM NTC or HYOU1-targeting siRNA.
Seventy-two hours posttransfection, media were replaced with serum-free
EBM-2 without supplements and a Nikon Eclipse Ti inverted microscope
was used to obtain bright-field images of the cells at a 40 or 100
magnification. Media were replaced with fresh serum-free media before
each time point to remove dead cell debris.
Cytotoxicity assay. Three thousand cells/well of stable empty-vector-
or vIL-6-expressing hTERT-HUVEC were plated and transfected in two
white-walled 96-well plates using RNAiMAX and 100 nM NTC or
HYOU1-targeting siRNA according to the manufacturer’s protocol for
reverse transfection (Invitrogen). Samples were transfected in triplicate.
Three days posttransfection, one plate was used to measure baseline cyto-
toxicity at day 0 using the CytoTox-Glo kit (Promega) per the manufac-
turer’s instructions with a FLUOstar Optima luminometer (BMG
Labtech). The medium of the second plate was replaced with serum-free
EBM-2 without supplements for 6 days, followed by a second cytotoxicity
assay. The percentage of dead cells at each time point was calculated from
the raw data. Data are shown as fold changes in cell death, which was
calculated by dividing the percentage of dead cells at day 6 by the percent-
age at day 0. Error bars represent the standard deviations of the means,
and a one-way analysis of variance (ANOVA) with Tukey’s post hoc test
was used to compare all samples, with a P value of 0.05 considered
significant.
RESULTS
Identification of HYOU1 as a vIL-6 binding partner. The biolog-
ical effects of extracellular vIL-6 have been extensively studied (9,
16, 18, 20–22), but less is known about vIL-6’s interactions with
intracellular proteins. We sought to identify additional cellular
proteins that bind to vIL-6 and impact its function. We cloned
vIL-6 with an N-terminal FLAG tag into the pcDNA3.1 vector
(pcDNA3.1-vIL-6) and transfected the pcDNA3.1 empty vector
or pcDNA3.1-vIL-6 into HEK293T cells. Cells were harvested and
subjected to an immunoprecipitation with FLAG antibody-con-
jugated beads. vIL-6-bound proteins were eluted with 3X FLAG
peptide. A fraction of the elution was subjected to SDS-PAGE and
subsequent silver staining or Western blotting for vIL-6 to ensure
successful vIL-6 expression and pulldown (Fig. 1A). The vIL-6
concentration in the lysate was high enough that dimerization of
the vIL-6 protein was evident by Western blotting (Fig. 1A, right).
The remainder of the eluted samples was digested with trypsin and
analyzed by shotgun mass spectrometry (48). Proteins with pep-
tide counts that were higher in the vIL-6 –FLAG sample than in the
empty-vector sample were identified as potential vIL-6 binding
partners (Fig. 1B). Over 40 unique calnexin peptides and 9 unique
gp130 peptides were identified in the vIL-6 sample, consistent
with previous findings (28). The vIL-6 sample also had 9 unique
Modulation of KSHV vIL-6 by HYOU1
August 2014 Volume 88 Number 16 jvi.asm.org 9431
peptides identified for the protein hypoxia-upregulated protein 1
(HYOU1; ORP150), while no HYOU1 peptides were identified in
the empty vector control.
To confirm that HYOU1 interacts with vIL-6, we again trans-
fected HE293T cells with the empty vector or FLAG-tagged vIL-6
constructs. Lysates from these cells were immunoprecipitated
with HYOU1 antibody or rabbit IgG as a control, and bound
proteins were eluted by boiling the plates in Laemmli buffer. Elu-
ates and input samples were resolved on an SDS-PAGE gel and
analyzed by Western blotting. As seen in Fig. 1C, vIL-6 coimmu-
noprecipitated with HYOU1. To determine whether vIL-6 inter-
acts with HYOU1 in a more relevant cell type, BCBL1 PEL cells
were transduced with the lentivirus-expressing empty vector or
FLAG-tagged vIL-6 and lysates were harvested 48 h later. The
FLAG-tagged vIL-6 was immunoprecipitated by FLAG antibody-
conjugated beads, and bound proteins were eluted with FLAG
peptide. Our data again showed that HYOU1 coimmunoprecipi-
tated with vIL-6, suggesting that there is a bona fide interaction
between HYOU1 and vIL-6 in multiple cell types.
To determine whether HYOU1 is expressed in tumors associ-
ated with KSHV infection, sections of BC-1 PEL tumors grown in
immunodeficient mice (47) and human KS sections were stained
for HYOU1 using the DAB peroxide substrate. Matched tumor
sections were also stained for LANA to confirm KSHV infection.
HYOU1 and LANA staining were observed in both PEL xenografts
and KS lesions (Fig. 2A and B). In the PEL xenografts in particular,
HYOU1 displayed distinct perinuclear staining, which is consis-
tent with its ER localization (Fig. 2A).
HYOU1 increases vIL-6 levels. HYOU1 is an ER chaperone
protein (32), so we sought to determine whether its interaction
with vIL-6 influences endogenous vIL-6 protein levels. BCBL1
PEL cells were transduced with lentivirus expressing a nontarget-
ing control (NTC) shRNA or a HYOU1-targeting shRNA. Three
days postransduction, cells were treated with dimethyl sulfoxide
(DMSO) to maintain latency or 25 ng/ml 12-O-tetradecanoyl-
phorbol 13-acetate (TPA) to induce lytic reactivation for 24 h. Cell
lysates and media were harvested and analyzed by SDS-PAGE and
Western blotting. High levels of HYOU1 knockdown were
achieved with the HYOU1-targeting shRNA, and as expected,
vIL-6 levels were higher overall in lytic samples than in latent
samples since vIL-6 is induced during lytic reactivation (10) (Fig.
3A). We found that HYOU1 knockdown decreased endogenous
FIG 1 vIL-6 binds the ER chaperone protein hypoxia-upregulated protein 1 (HYOU1). (A) HEK293T cells were transfected with an empty vector (EV) or
FLAG-tagged vIL-6, and lysates were harvested for immunoprecipitation with FLAG antibody. Portions of the eluates were analyzed by SDS-PAGE and
subsequent silver staining (left) (lane M contains the molecular size markers) or Western blotting for vIL-6 (right). (B) HYOU1, calnexin, and gp130 were
identified as binding partners of vIL-6 by mass spectrometry. (C) HEK293T cells were transfected with the empty vector or vIL-6 constructs, and lysates were
harvested and immunoprecipitated (IP) with HYOU1 or rabbit IgG control antibody (ab). Bound proteins were eluted with Laemmli buffer. Samples were
analyzed by SDS-PAGE and Western blotting for the indicated proteins. (D) BCBL1 PEL cells were transduced with lentivirus expressing the empty vector or
FLAG-tagged vIL-6. Lysates were immunoprecipitated with FLAG antibody, and eluates and inputs were analyzed by SDS-PAGE and Western blotting for the
indicated proteins.
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vIL-6 protein levels in both lytic and latent BCBL1 cells (Fig. 3A).
Additionally, HYOU1 knockdown decreased levels of secreted
vIL-6 during reactivation. While this is likely due to the increased
levels of intracellular vIL-6 when HYOU1 is expressed, we cannot
rule out the possibility that HYOU1 also promotes the secretion of
vIL-6.
We also performed this experiment using TREx BCBL1 and
TREx BCBL1-RTA PEL lines that express a doxycycline-inducible
empty vector or RTA, respectively (42). The two TREx BCBL1 cell
lines were transduced with lentivirus expressing an NTC or a
HYOU1-targeting shRNA. After 72 h, cells received 1 g/ml doxy-
cycline for 24 h to induce lytic replication in the TREx BCBL1-
RTA cells while the TREx BCBL1 cells remained latent. Cell lysate
and media were harvested and analyzed by SDS-PAGE and West-
ern blotting for the proteins indicated in Fig. 3B. Knockdown of
HYOU1 in both latent TREx BCBL1 and lytic TREx BCBL1-RTA
cells reduced levels of intracellular and extracellular vIL-6, similar
to the results seen in BCBL1 PEL cells. Conversely, levels of LANA
did not significantly change with HYOU1 knockdown in both the
latent and the lytic cells. We also examined the levels of the lytic
proteins RTA and K8.1 in the reactivated cells and found that
HYOU1 knockdown did not impact the levels of these lytic pro-
teins.
To further investigate whether HYOU1 knockdown impacts
levels of vIL-6, we used HEK293 cells stably expressing an NTC or
a HYOU1-targeting shRNA. These cells were then transfected
with a titration of FLAG-tagged vIL-6 plasmid for 48 h. We also
performed a similar experiment by transiently transfecting
HEK293 cells with NTC or HYOU1-targeting siRNA for 24 h,
followed by transfection with a titration of FLAG-tagged vIL-6
plasmid for 48 h. Lysates from both of these experiments were
harvested and analyzed by Western blotting (Fig. 3C). In both of
these experiments, knockdown of HYOU1 prior to expression of
FLAG-tagged vIL-6 resulted in a reduction in vIL-6 expression
compared to that of cells that expressed endogenous levels of
HYOU1. These results closely match the phenotype that we see in
PEL cells endogenously expressing vIL-6 (Fig. 3A and B). Interest-
ingly, we find that when FLAG-tagged vIL-6 is expressed prior to
knockdown of HYOU1, vIL-6 levels do not appear to be signifi-
cantly changed by knockdown of HYOU1 (Fig. 4, 5C, 6B, and 7B).
For subsequent experiments, we chose to overexpress FLAG-
tagged vIL-6 before knocking down HYOU1 to keep the amount
of vIL-6 the same and eliminate differences in vIL-6 levels as a
variable contributing to the observed results. This approach al-
lowed us to determine whether HYOU1 actually affects vIL-6
function as opposed to simply affecting vIL-6 protein levels as a
mechanism of action.
HYOU1 facilitates vIL-6-dependent STAT signaling. Follow-
ing activation of gp130, STAT3 becomes phosphorylated at Y705.
This causes STAT3 to dimerize and relocate to the nucleus, where
FIG 2 HYOU1 is expressed in tissue from KSHV-associated tumors. (A) Immunohistochemical staining for HYOU1 and LANA on BC-1 PEL xenograft sections.
The control received no primary antibody. (B) Immunohistochemical staining for HYOU1 and LANA on sections of human KS lesions. The control received no
primary antibody. Magnifications are noted at the right.
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it upregulates IL-6-responsive proinflammatory genes. Others
have shown that vIL-6 induces STAT3 Y705 phosphorylation
through activation of gp130 (21, 28). To determine whether
HYOU1’s interaction with vIL-6 is involved in the induction of
this signaling cascade, HEK293 cells were transfected with the
empty vector or the FLAG-tagged vIL-6 plasmid and then trans-
fected with an NTC or HYOU1-targeting siRNA 24 h later. Twen-
ty-four hours after the siRNA transfection, media were replaced
FIG 3 HYOU1 increases endogenous vIL-6 levels. (A) BCBL1 PEL cells were transduced with lentivirus expressing a nontargeting control (NTC) or HYOU1-
targeting shRNA. Three days later, cells were treated with DMSO or 25 ng/ml TPA to induce reactivation for 24 h. Lysates and media were collected and analyzed
by SDS-PAGE and Western blotting for the indicated proteins. (B) TREx BCBL1 or TREx BCBL1-RTA PEL cells expressing the doxycycline (Dox)-inducible
empty vector or RTA, respectively, were transduced with lentivirus expressing an NTC or HYOU1-targeting shRNA. Three days postransduction, 1 g/ml
doxycycline was added for 24 h. Lysates and media were harvested and analyzed by SDS-PAGE and Western blotting for the indicated proteins. (C) HEK293 cells
stably knocked down for HYOU1 (left) or HEK293 cells first transfected with NTC or HYOU1-targeting siRNA (right) were then transfected with a titration of
FLAG-tagged vIL-6 plasmid for 48 h. Lysates were harvested and analyzed by SDS-PAGE and Western blotting for the indicated proteins.
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with serum-free media for another 24 h. Lysates were harvested
and analyzed by SDS-PAGE and Western blotting. vIL-6 increased
STAT3 Y705 phosphorylation in the presence of HYOU1, com-
pared to that of cells expressing the empty vector; however, knock-
down of HYOU1 diminished this phosphorylation event (Fig.
4A). We generated hTERT-HUVEC (43) stably expressing the
empty vector or FLAG-tagged vIL-6 and transfected these cells
with NTC or HYOU1-targeting siRNA for 3 days. These cells were
treated with plain EBM-2 medium containing 2% charcoal-fil-
tered FBS for 24 h prior to harvest to eliminate background levels
of STAT3 phosphorylation. Lysates from the hTERT-HUVEC
showed a trend similar to that of HEK293 cells for STAT3 phos-
phorylation (Fig. 4B). This suggests that HYOU1 is involved in
enhancing vIL-6-induced activation of the JAK/STAT signaling
pathway in multiple cell types.
Since vIL-6 can bind ER-embedded gp130 to initiate JAK/
STAT signaling (12), we hypothesized that HYOU1 may facilitate
vIL-6-induced STAT3 phosphorylation by promoting vIL-6’s in-
teraction with gp130. To test this, we used HEK293 cells stably
expressing an empty vector or FLAG-tagged vIL-6. Cells were
transfected with 75 nM NTC or HYOU1-targeting siRNA for 72 h.
Lysates were harvested and subjected to an immunoprecipitation
with FLAG beads to pull down vIL-6. Bound proteins were eluted
with FLAG peptide, and the eluates and input samples were ana-
lyzed by SDS-PAGE and Western blotting. We found that gp130
coimmunoprecipitated with vIL-6 as expected but that knock-
down of HYOU1 consistently reduced this interaction (Fig. 4C).
This suggests that HYOU1 promotes the vIL-6-gp130 interaction,
so this may be one mechanism by which HYOU1 facilitates vIL-
6-mediated STAT signaling.
HYOU1 is essential for vIL-6-induced endothelial cell migra-
tion. To further understand the impact of HYOU1 on vIL-6 ac-
tivity, we developed biological assays for vIL-6 function in endo-
thelial cells. KS is a cancer of endothelial cell origin, and vIL-6 can
be detected in patients with this malignancy (13). Therefore, en-
dothelial cells are a relevant model for studying vIL-6 function.
We first investigated whether vIL-6 can influence endothelial cell
migration in a scratch assay. Equivalent numbers of hTERT-HU-
VEC stably expressing an empty vector or FLAG-tagged vIL-6
were plated as a confluent monolayer and serum starved overnight
before the monolayer was scratched with a P10 pipette tip. The
scratch was monitored at various time points by utilizing bright-
field microscopy on a Nikon Eclipse Ti inverted microscope. Cells
expressing vIL-6 were able to close the scratch faster than cells
expressing the empty vector (Fig. 5A). The influence of vIL-6 ex-
pression on endothelial cell migration has not been previously
studied, so these data represent a novel biological function for
vIL-6.
We extended this assay to study the effect of HYOU1 on vIL-
6-induced endothelial cell migration. hTERT-HUVEC stably ex-
pressing the empty vector or FLAG-tagged vIL-6 were transduced
with lentivirus expressing an NTC or a HYOU1-targeting shRNA.
Two days postransduction, cells were serum starved overnight
prior to scratching of the monolayer. Again, when HYOU1 was
expressed normally, the vIL-6-expressing cells closed the scratch
more rapidly than the empty-vector-expressing cells (Fig. 5B).
However, vIL-6-expressing cells knocked down for HYOU1 were
unable to close the gap, as with the empty-vector-expressing cells
(Fig. 5B). The area of each scratch was quantified with ImageJ
software (Fig. 5C). Lysates were harvested from these cells and
subjected to SDS-PAGE and Western blotting to confirm HYOU1
knockdown and vIL-6 expression (Fig. 5D). These data suggest
that HYOU1 is critical for vIL-6-induced migration of endothelial
cells.
To elucidate the mechanism by which vIL-6 induces endothe-
lial cell migration, we investigated whether vIL-6 affects the levels
of chemokine (C-C motif) ligand 2 (CCL2, also called monocyte
chemoattractant protein 1, or MCP1) since this chemokine is as-
sociated with tumor cell migration and metastasis and increased
FIG 4 HYOU1 enhances vIL-6-induced STAT3 signaling. (A) HEK293 cells
were transfected with an empty vector (EV) or FLAG-tagged vIL-6 plasmids
followed by a transfection with nontargeting control (NTC) or HYOU1-tar-
geting siRNA 24 h later. Twenty-four hours after siRNA transfection, cells were
serum starved for another 24 h. Lysates were harvested and analyzed by SDS-
PAGE and Western blotting for the indicated proteins. (B) hTERT-HUVEC
stably expressing the empty vector or FLAG-tagged vIL-6 were transfected
with NTC or HYOU1-targeting siRNA for 3 days. Media were replaced with
plain EBM-2 with 2% charcoal-filtered FBS for 24 h. Lysates were harvested
and analyzed by SDS-PAGE and Western blotting. (C) HEK293 stably express-
ing the empty vector or FLAG-tagged vIL-6 were transfected with 75 nM NTC
or HYOU1 siRNA for 3 days. Lysates were harvested and subjected to a FLAG
immunoprecipitation overnight. Bound proteins were eluted with 3X FLAG
peptide, and eluates and input samples were analyzed by SDS-PAGE and West-
ern blotting for the indicated proteins.
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vascular permeability (40, 41). We transfected hTERT-HUVEC
stably expressing an empty vector or FLAG-tagged vIL-6 with 100
nM NTC or HYOU1-targeting siRNA for 72 h, followed by serum
starvation for 48 h. We performed a CCL2 ELISA on supernatants
from these cells and found that vIL-6 expression increases the level
of extracellular CCL2 compared to the level with the empty vector
(Fig. 5E). Interestingly, knockdown of HYOU1 in vIL-6 cells
caused the CCL2 level to decrease substantially, although the level
of CCL2 in this sample was still higher than the level seen in
hTERT-HUVEC expressing the empty vector (Fig. 5E). This sug-
gests that there may be factors besides CCL2 that are involved in
vIL-6-mediated cell migration.
HYOU1 is required for vIL-6-mediated endothelial cell sur-
vival. We next investigated vIL-6’s role in endothelial cell survival
under serum-starved conditions. hTERT-HUVEC stably express-
ing the empty vector or FLAG-tagged vIL-6 were transfected with
FIG 5 HYOU1 facilitates vIL-6-induced migration of endothelial cells. (A) hTERT-HUVEC stably expressing an empty vector (EV) or FLAG-tagged vIL-6 were
serum starved overnight and scratched with a P10 pipette. Scratch closure was monitored at 0, 4, 8, 12, and 24 h by bright-field microscopy at 100 magnification
using a Nikon Eclipse Ti inverted microscope. (B) hTERT-HUVEC stably expressing the empty vector or FLAG-tagged vIL-6 were transduced with lentivirus
expressing a nontargeting control (NTC) or HYOU1-targeting shRNA. Cells were serum starved overnight, scratched with a P10 pipette tip, and monitored for
scratch closure at 0, 6, 12, and 24 h at 40 magnification. (C) Quantification of the area of each scratch pictured in panel B normalized to the 0-h time point. (D)
Lysates from the cells described in panel B were harvested at the 24-h time point and analyzed by SDS-PAGE and Western blotting to confirm efficient HYOU1
knockdown and vIL-6 expression. (E) hTERT-HUVEC stably expressing the empty vector or FLAG-tagged vIL-6 were transfected with 50 nM NTC or
HYOU1-targeting siRNA for 3 days, followed by serum starvation for 48 h. Supernatants were collected, and a CCL2 ELISA was performed, with each sample
tested in triplicate. Absorbance was read at 450 nm, and a standard curve was generated using a best-fit power trendline in Microsoft Excel. The concentrations
of the samples were calculated, and error bars represent standard deviations of the results from triplicates. A two-tailed Student t test was used to compare the
sample concentrations, with a P value of 0.05 considered significant. Results are representative of at least 3 experiments.
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100 nM NTC or HYOU1-targeting siRNA. Seventy-two hours
posttransfection, cells were serum starved and bright-field images
were obtained at the time points indicated in Fig. 6. vIL-6 express-
ing cells expressing HYOU1 maintained normal morphology, re-
mained adherent, and survived significantly longer under serum-
free conditions than cells expressing the empty vector (Fig. 6A).
HYOU1 knockdown had little impact on survival in cells express-
ing the empty vector. However, vIL-6-expressing cells with
HYOU1 knockdown displayed significantly reduced survival
compared to that of vIL-6 cells expressing HYOU1 (Fig. 6A). Ly-
sates from a duplicate set of samples were harvested for analysis by
SDS-PAGE and Western blotting to ensure adequate HYOU1
knockdown and vIL-6 expression (Fig. 6B).
To quantify the effect of HYOU1 on vIL-6-induced survival,
we performed a luminescence-based cytotoxicity assay. hTERT-
HUVEC stably expressing the empty vector or FLAG-tagged vIL-6
were reverse transfected with 100 nM NTC or HYOU1 siRNA in
triplicate in two 96-well white-walled plates. Three days post-
transfection, the cytotoxicity assay was performed on one plate
(day 0 reading). At this time point, the levels of cell death were
comparable between all samples (data not shown). The second
plate was serum starved for 6 days, and another cytotoxicity assay
was performed. The percentages of dead cells at day 0 and day 6
were calculated as per the manufacturer’s instructions. A fold
change in dead cells was calculated by dividing the percentage of
dead cells at day 6 by the percentage at day 0. As with trends seen
in the serum-starved survival assay (Fig. 6A), empty vector cells
receiving NTC siRNA have a statistically significant increase in cell
death after 6 days of serum starvation compared to that of vIL-6-
expressing cells receiving the NTC siRNA (Fig. 6C). HYOU1
knockdown had little impact on the survival of cells expressing the
empty vector. However, knockdown of HYOU1 in vIL-6-express-
ing cells caused significantly higher levels of cell death after 6 days
of serum starvation than was seen with vIL-6 cells expressing
HYOU1 (Fig. 6C). Overall, these data suggest that HYOU1 is crit-
ical for vIL-6-mediated survival of serum-starved endothelial
cells.
HYOU1 influences the signaling of human IL-6. After con-
firming vIL-6’s interaction with HYOU1, we wanted to determine
whether hIL-6 can also interact with HYOU1. hIL-6 is rapidly
secreted (27), so intracellular levels are typically undetectable by
Western blotting. hIL-6 constructs that were either wild type or
tagged with an ER-targeting KDEL motif (12, 45) were transfected
into HEK293 cells. Lysates were harvested and subjected to an
immunoprecipitation with HYOU1 antibody, followed by SDS-
PAGE and Western blot analysis. We found that hIL-6 –KDEL,
but not wild-type hIL-6, coimmunoprecipitated with HYOU1
(Fig. 7A). The fact that an immunoprecipitated band for wild-type
FIG 6 HYOU1 is required for vIL-6-induced endothelial cell survival under serum-starved conditions. (A) hTERT-HUVEC stably expressing an empty vector
(EV) or FLAG-tagged vIL-6 were plated as a confluent monolayer and transfected with 100 nM nontargeting control (NTC) or HYOU1-targeting siRNA. Cells
were serum starved 72 h posttransfection, and bright-field images at a 100 magnification were taken at 0, 6, and 10 days poststarvation using a Nikon Eclipse
Ti inverted microscope. Replicate samples were harvested 24 h after starvation for analysis by SDS-PAGE and Western blotting to confirm efficient vIL-6
expression and HYOU1 knockdown (B). (C) hTERT-HUVEC stably expressing the empty vector or FLAG-tagged vIL-6 were reverse transfected with 100 nM
NTC or HYOU1-targeting siRNA in triplicate in two white-walled 96-well plates. Three days posttransfection, a CytoTox-Glo (Promega) cytotoxicity assay was
performed on the first plate and the percentage of dead cells at day 0 was calculated. The second plate was serum starved for 6 days, followed by completion of
a cytotoxicity assay used to calculate the percentage of dead cells at day 6. The graph represents a fold change in dead cells calculated by dividing the percentage
of dead cells at day 6 by the percentage of dead cells at day 0. Error bars represent standard deviations of the means, and P values were calculated using a one-way
ANOVA with Tukey’s post hoc test to compare all values to each other, with a P value of 0.05 considered significant. These data are representative of 3
independent experiments.
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hIL-6 was not visible is not surprising, since no wild-type hIL-6
was identified in the input lysates, whereas high levels of hIL-
6 –KDEL were observed in the lysates (Fig. 7A). Therefore,
HYOU1 can interact with hIL-6 only when this cytokine is
retained in the ER.
Since we detected an interaction between HYOU1 and hIL-6 –
KDEL, we investigated whether HYOU1 impacts wild-type and
KDEL-tagged hIL-6 signaling through the JAK/STAT pathway.
HEK293 cells were transfected with an empty vector, FLAG-
tagged vIL-6, wild-type hIL-6, or hIL-6 –KDEL for 24 h, followed
by an additional transfection with either NTC or HYOU1-target-
ing siRNA. One day later, cells were serum starved for 24 h and
lysates were harvested and subjected to SDS-PAGE and Western
blotting. Expression of vIL-6 and wild-type hIL-6 increased
STAT3 Y705 phosphorylation (Fig. 7B). hIL-6 –KDEL also in-
duced STAT3 phosphorylation, which is likely due to leaky ex-
pression of hIL-6 –KDEL into the media in our experimental
system (Fig. 7A). Knockdown of HYOU1 decreased STAT3 phos-
phorylation mediated by vIL-6, wild-type hIL-6, and hIL-6 –
KDEL (Fig. 7B). This suggests that HYOU1 not only impacts vIL-6
signaling events but also may influence signaling by hIL-6.
DISCUSSION
KSHV expresses several homologs of human cytokines and
chemokines, including vIL-6 and multiple viral CC chemokines
(vCCLs, previously called viral macrophage inflammatory pro-
teins [vMIPs]) (9). vIL-6 shares considerable structural and func-
tional homology with hIL-6 and is detectable in all KSHV-associ-
ated malignancies (7, 13, 14). Patients with these malignancies
also have elevated hIL-6 levels (49), and vIL-6 signaling likely pro-
motes the proinflammatory signaling of hIL-6 to exacerbate dis-
ease. Inhibition of hIL-6 signaling to treat KSHV-associated lym-
phomas has been successful (50), so it is plausible that targeting
vIL-6 signaling may also be a viable treatment for KSHV-associ-
ated malignancies.
Many previous reports on vIL-6 used exogenously applied
vIL-6 (16, 18, 20–22). Although this has given valuable insight into
the role of this viral cytokine, recent publications suggest that
vIL-6 is retained primarily within the host cell in the ER (12, 27).
Evidence that supports this intracellular retention include the fact
that vIL-6 is secreted at a much lower rate than hIL-6, has glyco-
sylation patterns distinct from those seen on secreted cytokines,
and is capable of binding intracellular gp130 to induce signaling
(27, 51).
We utilized affinity purification and mass spectrometry to
identify cellular vIL-6 binding partners. HYOU1 stood out as a
potential hit because it had the same number of unique peptides as
were seen for gp130. HYOU1 is an ER chaperone that facilitates
protein processing, is involved in the ER stress response, and pro-
tects cells from hypoxia-induced cell death (32, 33, 38). KSHV-
associated malignancies often persist in hypoxic environments,
such as KS lesions on the lower extremities and PEL cells in oxy-
gen-deprived pleural cavities. Hypoxia is able to induce lytic rep-
lication due to hypoxia response elements present in the promoter
region of multiple lytic genes (37). Hypoxic conditions in KSHV-
infected cells or tumors may create a favorable environment for
high HYOU1 expression and function, making HYOU1 a relevant
protein to investigate in KSHV pathogenesis.
Based on HYOU1’s role as a chaperone protein for other se-
creted factors (39), we tested whether it modulates the level of
vIL-6 in the cell. We found that knockdown of HYOU1 reduces
endogenous vIL-6 protein levels in latent and lytic PEL cells as well
as in HEK293 cells when HYOU1 is knocked down prior to trans-
fection with a vIL-6 expression construct. Interestingly, in cells
that exogenously express vIL-6 before knockdown of HYOU1, the
effect of HYOU1 on vIL-6 expression is not significant. Based on
HYOU1’s role as a known processing factor for VEGF (39), we
speculate that HYOU1 may be involved in the processing and/or
stability of vIL-6, as well as the biological function of vIL-6.
Our data also show that HYOU1 enhances vIL-6-mediated
STAT3 phosphorylation, and it is known that vIL-6 can initiate
STAT signaling through ER-associated gp130 (12). We hypothe-
sized that HYOU1’s interaction with vIL-6 may place vIL-6 in
closer proximity to gp130 as a mechanism to promote signaling.
To test this, we performed an immunoprecipitation and found
that HYOU1 expression appears to increase the ability of vIL-6 to
bind gp130. In addition to increasing intracellular vIL-6 levels,
promoting the vIL-6-gp130 interaction may be yet another way
that HYOU1 is able to positively influence vIL-6 function.
FIG 7 HYOU1 interacts with and influences the signaling of hIL-6. (A)
HEK293 cells were transfected with an empty vector (EV), vIL-6, wild-type
hIL-6, or hIL-6 with a KDEL motif (hIL-6 –KDEL). Lysates were harvested and
immunoprecipitated with a HYOU1 antibody. Eluates were subjected to SDS-
PAGE and Western blotting for the indicated proteins. Input lysates and media
were analyzed for intracellular expression of HYOU1, vIL-6, and hIL-6. (B)
HEK293 cells were transfected with the empty vector, vIL-6, wild-type hIL-6,
or hIL-6 –KDEL for 24 h, followed by transfection with 100 nM nontargeting
or HYOU1-targeting siRNA for an additional 24 h. Cells were serum starved
overnight, and lysates and media were harvested for analysis by SDS-PAGE
and Western blotting for the indicated proteins.
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KS lesions are of endothelial cell origin and exist in a highly in-
flammatory and vascularized environment (52, 53). vIL-6 expression
is detectable in the sera of a proportion of KS patients (13), and vIL-6
has been shown to influence important biological functions of endo-
thelial cells, such as differentiation, proliferation, and angiogenesis
(19, 54). Our data further show that vIL-6 is able to induce the mi-
gration of endothelial cells in a HYOU1-dependent manner. For this
assay, we used serum-starved cells to minimize the possibility that
proliferating cells, as opposed to migrating cells, filled the gap, since
vIL-6 has previously been shown to increase cell proliferation (12, 16,
19, 20). HYOU1 has a known role in facilitating processing of secreted
factors, including VEGF (39). We therefore hypothesized that
HYOU1 modulates chemokines involved in vIL-6-mediated cell mi-
gration. CCL2 is associated with increased migration of tumor cells
and immune cells (40, 41). We found that vIL-6 can induce CCL2
expression and that knockdown of HYOU1 substantially reduced this
vIL-6-mediated increase in CCL2, but not quite to the level of CCL2
in cells expressing an empty vector. This suggests that HYOU1 may
partly influence vIL-6-mediated migration by modulating CCL2 ex-
pression but that other chemokines or factors are likely involved.
Overall, our data suggest that HYOU1 may have multiple mecha-
nisms by which it promotes vIL-6 function in signaling, endothelial
cell migration, and endothelial cell survival under serum-starved
conditions.
Since vIL-6 is a homolog of hIL-6, we tested whether HYOU1 can
also bind the human cytokine. Because hIL-6 is rapidly secreted, it is
present at levels that are undetectable by Western blotting in cell ly-
sates. Therefore, we speculated that it would be difficult to demon-
strate an interaction between wild-type hIL-6 and HYOU1, since
such an interaction would likely be too transient to detect. We cir-
cumvented this issue by using an hIL-6 construct with an ER-target-
ing KDEL motif that increases the intracellular retention of hIL-6. We
detected an interaction between HYOU1 and hIL-6–KDEL, al-
though we could not detect an interaction between wild-type hIL-6
and HYOU1. However, we found that STAT3 signaling mediated by
wild-type hIL-6 was diminished when HYOU1 was depleted from
cells. Since HYOU1 can impact wild-type hIL-6 signaling, we specu-
late that HYOU1 might transiently interact with hIL-6 when the cy-
tokine transits through the ER, despite our being unable to see an
interaction between HYOU1 and wild-type hIL-6 by immunopre-
cipitation. Alternatively, HYOU1 might have an effect on other com-
ponents of the hIL-6 signaling pathway to impact signaling. Overall,
our data suggest that HYOU1 may play a role in both vIL-6 and hIL-6
signaling function.
During lytic reactivation of KSHV, vIL-6 is highly expressed,
and some is secreted from infected cells, which is likely why pa-
tients with MCD and other KSHV-associated malignancies have
detectable vIL-6 in their serum (14, 15). Conversely, during la-
tency, vIL-6 is expressed at very low levels that are retained mainly
within the cell. Importantly, it has been demonstrated that this
low level of latent expression is functional (12). Inhibition of pro-
inflammatory hIL-6 signaling with an anti-IL-6 receptor antibody
has been moderately successful for the treatment of MCD (50);
however, inhibiting vIL-6 signaling in a similar fashion may be
challenging, since a portion of vIL-6 signaling occurs inside the
cell beyond reach of an IL6R-targeting antibody. The identifica-
tion of HYOU1 as a cellular binding partner that is required for
facilitating multiple facets of vIL-6 function and hIL-6 activity
presents an alternative druggable target for inhibiting IL-6 func-
tion in the treatment of KSHV-associated malignancies.
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